NCT00520260View on ClinicalTrials.gov

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Dry Eye DiseaseOcular Comfort
Interventions
DRUG

bromfenac

0.09%, BID, 6 weeks

DRUG

ketorolac

0.4%, BID, 6 weeks

Trial Locations (1)

33426

Florida Eye Microsurgical Institute, Boynton Beach

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

Florida Eye Microsurgical Institute

OTHER

NCT00520260 - Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase | Biotech Hunter | Biotech Hunter